{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T12:21:22Z","timestamp":1756902082536,"version":"3.44.0"},"reference-count":9,"publisher":"The Pediatric Pharmacy Association","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021]]},"abstract":"<jats:sec>\n          <jats:title>OBJECTIVE<\/jats:title>\n          <jats:p>The lack of randomized controlled trials comparing biologics for the treatment of juvenile idiopathic arthritis (JIA) has led to wide variation in treatment approaches. The objective of this study is to compare the efficacy and safety of abatacept, adalimumab, and etanercept in JIA patients treated at a tertiary pediatric institution.<\/jats:p>\n        <\/jats:sec>\n        <jats:sec>\n          <jats:title>METHODS<\/jats:title>\n          <jats:p>This was a single-center, retrospective chart review of patients initiated on abatacept, adalimumab, or etanercept from December 1, 2015, to August 31, 2018, at Monroe Carell Jr. Children's Hospital at Vanderbilt (VCH). The primary outcome was the change in the Physician Global Assessment (PGA) score after 4 to 6 months of biologic therapy. Secondary outcomes included change in laboratory markers of JIA disease activity, change in the number of joints with active disease or limitation of motion, reduction in corticosteroid dose, adverse effects, adherence among patients who have their medications filled at the institution's specialty pharmacy, and reason for discontinuation of therapy.<\/jats:p>\n        <\/jats:sec>\n        <jats:sec>\n          <jats:title>RESULTS<\/jats:title>\n          <jats:p>A total of 139 patients were included, with a median age of 13 years. Most patients, 80.6%, experienced a reduction in their PGA score after starting biologic therapy. There was not a statistically significant difference among the agents (p = 0.64). Adverse effects were reported in only 26.6% of patients, with the most frequent being injection site reactions or pain (n = 35). Ultimately, 32% of patients discontinued biologic therapy with a lack of efficacy being the most common reason.<\/jats:p>\n        <\/jats:sec>\n        <jats:sec>\n          <jats:title>CONCLUSIONS<\/jats:title>\n          <jats:p>Abatacept, adalimumab, and etanercept were not significantly different in efficacy and safety for the treatment of JIA at this single institution.<\/jats:p>\n        <\/jats:sec>","DOI":"10.5863\/1551-6776-26.2.157","type":"journal-article","created":{"date-parts":[[2021,2,16]],"date-time":"2021-02-16T22:22:55Z","timestamp":1613514175000},"page":"157-162","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy and Safety of Abatacept, Adalimumab, and Etanercept in Pediatric Patients With Juvenile Idiopathic Arthritis"],"prefix":"10.5863","volume":"26","author":[{"given":"Andrea M.","family":"Goettel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josh","family":"DeClercq","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leena","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas B.","family":"Graham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy A.","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3883","reference":[{"issue":"4","key":"i1551-6776-26-2-157-b1","series-title":"Arthritis Care Res","first-page":"465","article-title":"2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features","volume":"63","year":"2011","unstructured":"Beukelman\n              T,\n            \n            \n              Patkar\n              NM,\n            \n            \n              Saag\n              KG,\n            \n          \n          .\n\t\t\t\t\t2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features.\n\t\t\t\t\tArthritis Care Res.\n\t\t\t\t\t2011;\n\t\t\t\t\t63(\n\t\t\t\t\t4):\n\t\t\t\t\t465\u2013\n\t\t\t\t\t482."},{"issue":"6","key":"i1551-6776-26-2-157-b2","series-title":"Arthritis Care Res","first-page":"717","article-title":"2019 American College of Rheumatology\/Arthritis Foundation Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Non-Systemic Polyarthritis, Sacroiliitis, and Enthesitis","volume":"71","year":"2019","unstructured":"Ringold\n              S,\n            \n            \n              Angeles-Han\n              ST,\n            \n            \n              Beukelman\n              T,\n            \n          \n          .\n\t\t\t\t\t2019 American College of Rheumatology\/Arthritis Foundation Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Non-Systemic Polyarthritis, Sacroiliitis, and Enthesitis.\n\t\t\t\t\tArthritis Care Res.\n\t\t\t\t\t2019;\n\t\t\t\t\t71(\n\t\t\t\t\t6):\n\t\t\t\t\t717\u2013\n\t\t\t\t\t734."},{"issue":"2","key":"i1551-6776-26-2-157-b3","series-title":"Arthritis Care Res","first-page":"268","article-title":"Prescribing for children with rheumatic disease: perceived treatment approaches between pediatric and adult rheumatologists","volume":"70","year":"2018","unstructured":"van Mater\n              H,\n            \n            \n              Balevic\n              SJ,\n            \n            \n              Freed\n              GL,\n            \n            \n              Clark\n              SJ.\n            \n          \n          Prescribing for children with rheumatic disease: perceived treatment approaches between pediatric and adult rheumatologists.\n\t\t\t\t\tArthritis Care Res.\n\t\t\t\t\t2018;\n\t\t\t\t\t70(\n\t\t\t\t\t2):\n\t\t\t\t\t268\u2013\n\t\t\t\t\t274."},{"issue":"1","key":"i1551-6776-26-2-157-b4","series-title":"Arthritis Res Ther","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1186\/s13075-016-1170-3","article-title":"Comparison of treatment response, remission rate and drug adherence in polyarticular juvenile idiopathic arthritis patients treated with etanercept, adalimumab or tocilizumab","volume":"18","year":"2016","unstructured":"Horneff\n              G,\n            \n            \n              Klein\n              A,\n            \n            \n              Klotsche\n              J,\n            \n          \n          .\n\t\t\t\t\tComparison of treatment response, remission rate and drug adherence in polyarticular juvenile idiopathic arthritis patients treated with etanercept, adalimumab or tocilizumab.\n\t\t\t\t\tArthritis Res Ther.\n\t\t\t\t\t2016;\n\t\t\t\t\t18(\n\t\t\t\t\t1):\n\t\t\t\t\t272.\n\t\t\t\t\tdoi:10.1186\/s13075-016-1170-3"},{"issue":"34","key":"i1551-6776-26-2-157-b5","series-title":"Health Technol Assess","first-page":"1","article-title":"The clinical effectiveness and cost-effectiveness of abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis: a systematic review and economic evaluation","volume":"20","year":"2016","unstructured":"Shepherd\n              J,\n            \n            \n              Cooper\n              K,\n            \n            \n              Harris\n              P,\n            \n          \n          .\n\t\t\t\t\tThe clinical effectiveness and cost-effectiveness of abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis: a systematic review and economic evaluation.\n\t\t\t\t\tHealth Technol Assess.\n\t\t\t\t\t2016;\n\t\t\t\t\t20(\n\t\t\t\t\t34):\n\t\t\t\t\t1\u2013\n\t\t\t\t\t222."},{"issue":"1","key":"i1551-6776-26-2-157-b6","series-title":"Pediatr Rheumatol Online J","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s12969-016-0085-5","article-title":"Clinical outcome measures in juvenile idiopathic arthritis","volume":"14","year":"2016","unstructured":"Consolaro\n              A,\n            \n            \n              Giancane\n              G,\n            \n            \n              Schiappapietra\n              B,\n            \n          \n          .\n\t\t\t\t\tClinical outcome measures in juvenile idiopathic arthritis.\n\t\t\t\t\tPediatr Rheumatol Online J.\n\t\t\t\t\t2016;\n\t\t\t\t\t14(\n\t\t\t\t\t1):\n\t\t\t\t\t23.\n\t\t\t\t\tdoi:10.1186\/s12969-016-0085-5"},{"issue":"9","key":"i1551-6776-26-2-157-b7","series-title":"Eur J Immunol","first-page":"2068","article-title":"Understanding inflammation in juvenile idiopathic arthritis: how immune biomarkers guide clinical strategies in the systemic onset subtype","volume":"46","year":"2016","unstructured":"Swart\n              JF,\n            \n            \n              de Roock\n              S,\n            \n            \n              Prakken\n              BJ.\n            \n          \n          Understanding inflammation in juvenile idiopathic arthritis: how immune biomarkers guide clinical strategies in the systemic onset subtype.\n\t\t\t\t\tEur J Immunol.\n\t\t\t\t\t2016;\n\t\t\t\t\t46(\n\t\t\t\t\t9):\n\t\t\t\t\t2068\u2013\n\t\t\t\t\t2077."},{"issue":"2","key":"i1551-6776-26-2-157-b8","series-title":"J Rheumatol","first-page":"390","article-title":"International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001","volume":"31","year":"2004","unstructured":"Petty\n              RE,\n            \n            \n              Southwood\n              TR,\n            \n            \n              Manners\n              P,\n            \n          \n          .\n\t\t\t\t\tInternational League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001.\n\t\t\t\t\tJ Rheumatol.\n\t\t\t\t\t2004;\n\t\t\t\t\t31(\n\t\t\t\t\t2):\n\t\t\t\t\t390\u2013\n\t\t\t\t\t392."},{"issue":"6","key":"i1551-6776-26-2-157-b9","series-title":"Arthritis Rheumatol","first-page":"957","article-title":"Brief report: the genetic profile of rheumatoid factor-positive polyarticular juvenile idiopathic arthritis resembles that of adult rheumatoid arthritis","volume":"70","year":"2018","unstructured":"Hinks\n              A,\n            \n            \n              Marion\n              MC,\n            \n            \n              Cobb\n              J,\n            \n          \n          .\n\t\t\t\t\tBrief report: the genetic profile of rheumatoid factor-positive polyarticular juvenile idiopathic arthritis resembles that of adult rheumatoid arthritis.\n\t\t\t\t\tArthritis Rheumatol.\n\t\t\t\t\t2018;\n\t\t\t\t\t70(\n\t\t\t\t\t6):\n\t\t\t\t\t957\u2013\n\t\t\t\t\t962."}],"container-title":["The Journal of Pediatric Pharmacology and Therapeutics"],"original-title":[],"link":[{"URL":"https:\/\/jppt.kglmeridian.com\/view\/journals\/jppt\/26\/2\/article-p157.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/meridian.allenpress.com\/jppt\/article-pdf\/26\/2\/157\/2773514\/i1551-6776-26-2-157.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jppt.kglmeridian.com\/downloadpdf\/journals\/jppt\/26\/2\/article-p157.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jppt.kglmeridian.com\/downloadpdf\/journals\/jppt\/26\/2\/article-p157.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T00:44:22Z","timestamp":1747356262000},"score":1,"resource":{"primary":{"URL":"https:\/\/jppt.kglmeridian.com\/view\/journals\/jppt\/26\/2\/article-p157.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"references-count":9,"journal-issue":{"issue":"2"},"URL":"https:\/\/doi.org\/10.5863\/1551-6776-26.2.157","relation":{},"ISSN":["1551-6776"],"issn-type":[{"type":"print","value":"1551-6776"}],"subject":[],"published":{"date-parts":[[2021]]}}}